The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Kidney Disease Drugs Market Research Report 2024

Global Kidney Disease Drugs Market Research Report 2024

Publishing Date : May, 2024

License Type :
 

Report Code : 1610128

No of Pages : 105

Ask Your Query

Synopsis

The global Kidney Disease Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Kidney Disease Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Disease Drugs.

Report Scope

The Kidney Disease Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Disease Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Kidney Disease Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

  • GlaxoSmithKline
  • Sanofi
  • Roche
  • Pfizer
  • AstraZeneca
  • Keryx Biopharmaceuticals
  • Kissei Pharmaceutical
  • AbbVie
  • Amgen
  • Teva Pharmaceutical Industries
  • Tianjin Tongrentang Group
  • Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
  • Datong Liqun Pharmaceutical
  • Hebei Ruisen Pharmaceutical
  • Changxing Pharmaceutical
  • zhejiang Shengbokang Pharmaceutical

Segment by Type

  • Tablets
  • Capsule
  • Other

Segment by Application

  • Chronic Glomerulonephritis
  • Nephrotic Syndrome
  • Chronic Renal Failure
  • Kidney Stones
  • Renal Cyst (polycystic Kidney)
  • Diabetic Nephropathy
  • Hypertensive Nephropathy
  • Purpura Nephritis
  • Lupus Nephritis
  • Pediatric Kidney Disease

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Kidney Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Kidney Disease Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Index

1 Kidney Disease Drugs Market Overview
1.1 Product Overview and Scope of Kidney Disease Drugs
1.2 Kidney Disease Drugs Segment by Type
1.2.1 Global Kidney Disease Drugs Market Value Comparison by Type (2024-2030)
1.2.2 Tablets
1.2.3 Capsule
1.2.4 Other
1.3 Kidney Disease Drugs Segment by Application
1.3.1 Global Kidney Disease Drugs Market Value by Application: (2024-2030)
1.3.2 Chronic Glomerulonephritis
1.3.3 Nephrotic Syndrome
1.3.4 Chronic Renal Failure
1.3.5 Kidney Stones
1.3.6 Renal Cyst (polycystic Kidney)
1.3.7 Diabetic Nephropathy
1.3.8 Hypertensive Nephropathy
1.3.9 Purpura Nephritis
1.3.10 Lupus Nephritis
1.3.11 Pediatric Kidney Disease
1.4 Global Kidney Disease Drugs Market Size Estimates and Forecasts
1.4.1 Global Kidney Disease Drugs Revenue 2019-2030
1.4.2 Global Kidney Disease Drugs Sales 2019-2030
1.4.3 Global Kidney Disease Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Kidney Disease Drugs Market Competition by Manufacturers
2.1 Global Kidney Disease Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Kidney Disease Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Kidney Disease Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Kidney Disease Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Kidney Disease Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Kidney Disease Drugs, Product Type & Application
2.7 Kidney Disease Drugs Market Competitive Situation and Trends
2.7.1 Kidney Disease Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Kidney Disease Drugs Players Market Share by Revenue
2.7.3 Global Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Kidney Disease Drugs Retrospective Market Scenario by Region
3.1 Global Kidney Disease Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Kidney Disease Drugs Global Kidney Disease Drugs Sales by Region: 2019-2030
3.2.1 Global Kidney Disease Drugs Sales by Region: 2019-2024
3.2.2 Global Kidney Disease Drugs Sales by Region: 2025-2030
3.3 Global Kidney Disease Drugs Global Kidney Disease Drugs Revenue by Region: 2019-2030
3.3.1 Global Kidney Disease Drugs Revenue by Region: 2019-2024
3.3.2 Global Kidney Disease Drugs Revenue by Region: 2025-2030
3.4 North America Kidney Disease Drugs Market Facts & Figures by Country
3.4.1 North America Kidney Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Kidney Disease Drugs Sales by Country (2019-2030)
3.4.3 North America Kidney Disease Drugs Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Kidney Disease Drugs Market Facts & Figures by Country
3.5.1 Europe Kidney Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Kidney Disease Drugs Sales by Country (2019-2030)
3.5.3 Europe Kidney Disease Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Kidney Disease Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Kidney Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Kidney Disease Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Kidney Disease Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Kidney Disease Drugs Market Facts & Figures by Country
3.7.1 Latin America Kidney Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Kidney Disease Drugs Sales by Country (2019-2030)
3.7.3 Latin America Kidney Disease Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Kidney Disease Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Kidney Disease Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Kidney Disease Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Kidney Disease Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Kidney Disease Drugs Sales by Type (2019-2030)
4.1.1 Global Kidney Disease Drugs Sales by Type (2019-2024)
4.1.2 Global Kidney Disease Drugs Sales by Type (2025-2030)
4.1.3 Global Kidney Disease Drugs Sales Market Share by Type (2019-2030)
4.2 Global Kidney Disease Drugs Revenue by Type (2019-2030)
4.2.1 Global Kidney Disease Drugs Revenue by Type (2019-2024)
4.2.2 Global Kidney Disease Drugs Revenue by Type (2025-2030)
4.2.3 Global Kidney Disease Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Kidney Disease Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Kidney Disease Drugs Sales by Application (2019-2030)
5.1.1 Global Kidney Disease Drugs Sales by Application (2019-2024)
5.1.2 Global Kidney Disease Drugs Sales by Application (2025-2030)
5.1.3 Global Kidney Disease Drugs Sales Market Share by Application (2019-2030)
5.2 Global Kidney Disease Drugs Revenue by Application (2019-2030)
5.2.1 Global Kidney Disease Drugs Revenue by Application (2019-2024)
5.2.2 Global Kidney Disease Drugs Revenue by Application (2025-2030)
5.2.3 Global Kidney Disease Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Kidney Disease Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Corporation Information
6.1.2 GlaxoSmithKline Description and Business Overview
6.1.3 GlaxoSmithKline Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 GlaxoSmithKline Kidney Disease Drugs Product Portfolio
6.1.5 GlaxoSmithKline Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Kidney Disease Drugs Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Kidney Disease Drugs Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Kidney Disease Drugs Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 AstraZeneca
6.5.1 AstraZeneca Corporation Information
6.5.2 AstraZeneca Description and Business Overview
6.5.3 AstraZeneca Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 AstraZeneca Kidney Disease Drugs Product Portfolio
6.5.5 AstraZeneca Recent Developments/Updates
6.6 Keryx Biopharmaceuticals
6.6.1 Keryx Biopharmaceuticals Corporation Information
6.6.2 Keryx Biopharmaceuticals Description and Business Overview
6.6.3 Keryx Biopharmaceuticals Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Keryx Biopharmaceuticals Kidney Disease Drugs Product Portfolio
6.6.5 Keryx Biopharmaceuticals Recent Developments/Updates
6.7 Kissei Pharmaceutical
6.6.1 Kissei Pharmaceutical Corporation Information
6.6.2 Kissei Pharmaceutical Description and Business Overview
6.6.3 Kissei Pharmaceutical Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kissei Pharmaceutical Kidney Disease Drugs Product Portfolio
6.7.5 Kissei Pharmaceutical Recent Developments/Updates
6.8 AbbVie
6.8.1 AbbVie Corporation Information
6.8.2 AbbVie Description and Business Overview
6.8.3 AbbVie Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 AbbVie Kidney Disease Drugs Product Portfolio
6.8.5 AbbVie Recent Developments/Updates
6.9 Amgen
6.9.1 Amgen Corporation Information
6.9.2 Amgen Description and Business Overview
6.9.3 Amgen Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Amgen Kidney Disease Drugs Product Portfolio
6.9.5 Amgen Recent Developments/Updates
6.10 Teva Pharmaceutical Industries
6.10.1 Teva Pharmaceutical Industries Corporation Information
6.10.2 Teva Pharmaceutical Industries Description and Business Overview
6.10.3 Teva Pharmaceutical Industries Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Teva Pharmaceutical Industries Kidney Disease Drugs Product Portfolio
6.10.5 Teva Pharmaceutical Industries Recent Developments/Updates
6.11 Tianjin Tongrentang Group
6.11.1 Tianjin Tongrentang Group Corporation Information
6.11.2 Tianjin Tongrentang Group Kidney Disease Drugs Description and Business Overview
6.11.3 Tianjin Tongrentang Group Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Tianjin Tongrentang Group Kidney Disease Drugs Product Portfolio
6.11.5 Tianjin Tongrentang Group Recent Developments/Updates
6.12 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical
6.12.1 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Corporation Information
6.12.2 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Description and Business Overview
6.12.3 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Product Portfolio
6.12.5 Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Recent Developments/Updates
6.13 Datong Liqun Pharmaceutical
6.13.1 Datong Liqun Pharmaceutical Corporation Information
6.13.2 Datong Liqun Pharmaceutical Kidney Disease Drugs Description and Business Overview
6.13.3 Datong Liqun Pharmaceutical Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Datong Liqun Pharmaceutical Kidney Disease Drugs Product Portfolio
6.13.5 Datong Liqun Pharmaceutical Recent Developments/Updates
6.14 Hebei Ruisen Pharmaceutical
6.14.1 Hebei Ruisen Pharmaceutical Corporation Information
6.14.2 Hebei Ruisen Pharmaceutical Kidney Disease Drugs Description and Business Overview
6.14.3 Hebei Ruisen Pharmaceutical Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Hebei Ruisen Pharmaceutical Kidney Disease Drugs Product Portfolio
6.14.5 Hebei Ruisen Pharmaceutical Recent Developments/Updates
6.15 Changxing Pharmaceutical
6.15.1 Changxing Pharmaceutical Corporation Information
6.15.2 Changxing Pharmaceutical Kidney Disease Drugs Description and Business Overview
6.15.3 Changxing Pharmaceutical Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Changxing Pharmaceutical Kidney Disease Drugs Product Portfolio
6.15.5 Changxing Pharmaceutical Recent Developments/Updates
6.16 zhejiang Shengbokang Pharmaceutical
6.16.1 zhejiang Shengbokang Pharmaceutical Corporation Information
6.16.2 zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Description and Business Overview
6.16.3 zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Product Portfolio
6.16.5 zhejiang Shengbokang Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Kidney Disease Drugs Industry Chain Analysis
7.2 Kidney Disease Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Kidney Disease Drugs Production Mode & Process
7.4 Kidney Disease Drugs Sales and Marketing
7.4.1 Kidney Disease Drugs Sales Channels
7.4.2 Kidney Disease Drugs Distributors
7.5 Kidney Disease Drugs Customers
8 Kidney Disease Drugs Market Dynamics
8.1 Kidney Disease Drugs Industry Trends
8.2 Kidney Disease Drugs Market Drivers
8.3 Kidney Disease Drugs Market Challenges
8.4 Kidney Disease Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Kidney Disease Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Kidney Disease Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Kidney Disease Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Kidney Disease Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Kidney Disease Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Kidney Disease Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Kidney Disease Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Kidney Disease Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Kidney Disease Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Kidney Disease Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Kidney Disease Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Kidney Disease Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Kidney Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Disease Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Kidney Disease Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Kidney Disease Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Kidney Disease Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Kidney Disease Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Kidney Disease Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Kidney Disease Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Kidney Disease Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Kidney Disease Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Kidney Disease Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Kidney Disease Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Kidney Disease Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Kidney Disease Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Kidney Disease Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Kidney Disease Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Kidney Disease Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Kidney Disease Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Kidney Disease Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Kidney Disease Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Kidney Disease Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Kidney Disease Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Kidney Disease Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Kidney Disease Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Kidney Disease Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Kidney Disease Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Kidney Disease Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Kidney Disease Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Kidney Disease Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Kidney Disease Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Kidney Disease Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Kidney Disease Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Kidney Disease Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Kidney Disease Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Kidney Disease Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Kidney Disease Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Kidney Disease Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Kidney Disease Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Kidney Disease Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Kidney Disease Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Kidney Disease Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Kidney Disease Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Kidney Disease Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Kidney Disease Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Kidney Disease Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Kidney Disease Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Kidney Disease Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Kidney Disease Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Kidney Disease Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Kidney Disease Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Kidney Disease Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Kidney Disease Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Kidney Disease Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Kidney Disease Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Kidney Disease Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Kidney Disease Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. GlaxoSmithKline Corporation Information
Table 71. GlaxoSmithKline Description and Business Overview
Table 72. GlaxoSmithKline Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. GlaxoSmithKline Kidney Disease Drugs Product
Table 74. GlaxoSmithKline Recent Developments/Updates
Table 75. Sanofi Corporation Information
Table 76. Sanofi Description and Business Overview
Table 77. Sanofi Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Sanofi Kidney Disease Drugs Product
Table 79. Sanofi Recent Developments/Updates
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Roche Kidney Disease Drugs Product
Table 84. Roche Recent Developments/Updates
Table 85. Pfizer Corporation Information
Table 86. Pfizer Description and Business Overview
Table 87. Pfizer Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Pfizer Kidney Disease Drugs Product
Table 89. Pfizer Recent Developments/Updates
Table 90. AstraZeneca Corporation Information
Table 91. AstraZeneca Description and Business Overview
Table 92. AstraZeneca Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. AstraZeneca Kidney Disease Drugs Product
Table 94. AstraZeneca Recent Developments/Updates
Table 95. Keryx Biopharmaceuticals Corporation Information
Table 96. Keryx Biopharmaceuticals Description and Business Overview
Table 97. Keryx Biopharmaceuticals Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Keryx Biopharmaceuticals Kidney Disease Drugs Product
Table 99. Keryx Biopharmaceuticals Recent Developments/Updates
Table 100. Kissei Pharmaceutical Corporation Information
Table 101. Kissei Pharmaceutical Description and Business Overview
Table 102. Kissei Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Kissei Pharmaceutical Kidney Disease Drugs Product
Table 104. Kissei Pharmaceutical Recent Developments/Updates
Table 105. AbbVie Corporation Information
Table 106. AbbVie Description and Business Overview
Table 107. AbbVie Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. AbbVie Kidney Disease Drugs Product
Table 109. AbbVie Recent Developments/Updates
Table 110. Amgen Corporation Information
Table 111. Amgen Description and Business Overview
Table 112. Amgen Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Amgen Kidney Disease Drugs Product
Table 114. Amgen Recent Developments/Updates
Table 115. Teva Pharmaceutical Industries Corporation Information
Table 116. Teva Pharmaceutical Industries Description and Business Overview
Table 117. Teva Pharmaceutical Industries Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Teva Pharmaceutical Industries Kidney Disease Drugs Product
Table 119. Teva Pharmaceutical Industries Recent Developments/Updates
Table 120. Tianjin Tongrentang Group Corporation Information
Table 121. Tianjin Tongrentang Group Description and Business Overview
Table 122. Tianjin Tongrentang Group Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Tianjin Tongrentang Group Kidney Disease Drugs Product
Table 124. Tianjin Tongrentang Group Recent Developments/Updates
Table 125. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Corporation Information
Table 126. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Description and Business Overview
Table 127. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Kidney Disease Drugs Product
Table 129. Jiangxi Jimin Kexin Jinshuibao Pharmaceutical Recent Developments/Updates
Table 130. Datong Liqun Pharmaceutical Corporation Information
Table 131. Datong Liqun Pharmaceutical Description and Business Overview
Table 132. Datong Liqun Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Datong Liqun Pharmaceutical Kidney Disease Drugs Product
Table 134. Datong Liqun Pharmaceutical Recent Developments/Updates
Table 135. Hebei Ruisen Pharmaceutical Corporation Information
Table 136. Hebei Ruisen Pharmaceutical Description and Business Overview
Table 137. Hebei Ruisen Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Hebei Ruisen Pharmaceutical Kidney Disease Drugs Product
Table 139. Hebei Ruisen Pharmaceutical Recent Developments/Updates
Table 140. Changxing Pharmaceutical Corporation Information
Table 141. Changxing Pharmaceutical Description and Business Overview
Table 142. Changxing Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Changxing Pharmaceutical Kidney Disease Drugs Product
Table 144. Changxing Pharmaceutical Recent Developments/Updates
Table 145. zhejiang Shengbokang Pharmaceutical Corporation Information
Table 146. zhejiang Shengbokang Pharmaceutical Description and Business Overview
Table 147. zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. zhejiang Shengbokang Pharmaceutical Kidney Disease Drugs Product
Table 149. zhejiang Shengbokang Pharmaceutical Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Kidney Disease Drugs Distributors List
Table 153. Kidney Disease Drugs Customers List
Table 154. Kidney Disease Drugs Market Trends
Table 155. Kidney Disease Drugs Market Drivers
Table 156. Kidney Disease Drugs Market Challenges
Table 157. Kidney Disease Drugs Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Kidney Disease Drugs
Figure 2. Global Kidney Disease Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Kidney Disease Drugs Market Share by Type in 2023 & 2030
Figure 4. Tablets Product Picture
Figure 5. Capsule Product Picture
Figure 6. Other Product Picture
Figure 7. Global Kidney Disease Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Kidney Disease Drugs Market Share by Application in 2023 & 2030
Figure 9. Chronic Glomerulonephritis
Figure 10. Nephrotic Syndrome
Figure 11. Chronic Renal Failure
Figure 12. Kidney Stones
Figure 13. Renal Cyst (polycystic Kidney)
Figure 14. Diabetic Nephropathy
Figure 15. Hypertensive Nephropathy
Figure 16. Purpura Nephritis
Figure 17. Lupus Nephritis
Figure 18. Pediatric Kidney Disease
Figure 19. Global Kidney Disease Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global Kidney Disease Drugs Market Size (2019-2030) & (US$ Million)
Figure 21. Global Kidney Disease Drugs Sales (2019-2030) & (K Units)
Figure 22. Global Kidney Disease Drugs Average Price (US$/Unit) & (2019-2030)
Figure 23. Kidney Disease Drugs Report Years Considered
Figure 24. Kidney Disease Drugs Sales Share by Manufacturers in 2023
Figure 25. Global Kidney Disease Drugs Revenue Share by Manufacturers in 2023
Figure 26. The Global 5 and 10 Largest Kidney Disease Drugs Players: Market Share by Revenue in 2023
Figure 27. Kidney Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 28. Global Kidney Disease Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 29. North America Kidney Disease Drugs Sales Market Share by Country (2019-2030)
Figure 30. North America Kidney Disease Drugs Revenue Market Share by Country (2019-2030)
Figure 31. U.S. Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Canada Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Europe Kidney Disease Drugs Sales Market Share by Country (2019-2030)
Figure 34. Europe Kidney Disease Drugs Revenue Market Share by Country (2019-2030)
Figure 35. Germany Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. France Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. U.K. Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. Italy Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Russia Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Asia Pacific Kidney Disease Drugs Sales Market Share by Region (2019-2030)
Figure 41. Asia Pacific Kidney Disease Drugs Revenue Market Share by Region (2019-2030)
Figure 42. China Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Japan Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. South Korea Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. India Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Australia Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Taiwan Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Indonesia Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Thailand Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Malaysia Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Philippines Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 52. Latin America Kidney Disease Drugs Sales Market Share by Country (2019-2030)
Figure 53. Latin America Kidney Disease Drugs Revenue Market Share by Country (2019-2030)
Figure 54. Mexico Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Brazil Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Argentina Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 57. Middle East & Africa Kidney Disease Drugs Sales Market Share by Country (2019-2030)
Figure 58. Middle East & Africa Kidney Disease Drugs Revenue Market Share by Country (2019-2030)
Figure 59. Turkey Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 60. Saudi Arabia Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 61. UAE Kidney Disease Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 62. Global Sales Market Share of Kidney Disease Drugs by Type (2019-2030)
Figure 63. Global Revenue Market Share of Kidney Disease Drugs by Type (2019-2030)
Figure 64. Global Kidney Disease Drugs Price (US$/Unit) by Type (2019-2030)
Figure 65. Global Sales Market Share of Kidney Disease Drugs by Application (2019-2030)
Figure 66. Global Revenue Market Share of Kidney Disease Drugs by Application (2019-2030)
Figure 67. Global Kidney Disease Drugs Price (US$/Unit) by Application (2019-2030)
Figure 68. Kidney Disease Drugs Value Chain
Figure 69. Kidney Disease Drugs Production Process
Figure 70. Channels of Distribution (Direct Vs Distribution)
Figure 71. Distributors Profiles
Figure 72. Bottom-up and Top-down Approaches for This Report
Figure 73. Data Triangulation
Figure 74. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock